Advanced Search

Oncology & Hematology Coding Alert

YOU BE THE CODER ~ Report Post-Chemo Nausea Med?

Published on Thu Jan 11, 2007

Question: When Medicare patients receive an intravenous dose of ondansetron after a chemotherapy infusion session, may we report the ondansetron separately from the chemotherapy?

Wyoming Subscriber

Answer: Yes, you may report the ondansetron separately when you administer it post-chemo.
 
If you give a Medicare patient chemotherapy first (58-minute session), then administer the ondansetron, you should report:

- 96413 -- Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug - +90775 -- Therapeutic, prophylactic or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (list separately in addition to code for primary procedure). If you bear the cost of the drug, you should report it with the code for intravenous, not oral, ondansetron (Zofran), J2405 (Injection, ondansetron HCl, per 1 mg).
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All